Combined checkpoint immunotherapy and cytotoxic chemotherapy: Further results from a phase Ib/II trial of pembrolizumab and docetaxel or gemcitabine in patients with advanced or metastatic urothelial cancer

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2018
This article has no abstract
Epistemonikos ID: 0fff2808c984be014ac08a208f9e88bd4457da68
First added on: Feb 10, 2025